Subcommittee Meeting Concerning Marketing Approval for Oncolytic Virus OBP-301
Oncolys BioPharma Inc.
Oncolytic virus OBP-301 (Suratadenoturev), with esophageal cancer as the initial indication
None (there is no impact on the Company's financial results for the fiscal year ending December 2026)
Fiscal year ending December 2026
This matter will have no impact on the Company's financial results for the fiscal year ending December 2026. The Company plans to begin sales of OBP-301 as scheduled during the fiscal year ending December 2026.
Related procedures
Deliberation by the Pharmaceutical Affairs and Food Sanitation Council on whether to grant marketing approval and whether the product qualifies for conditional and time-limited approval
Ministry of Health, Labour and Welfare; Regenerative Medical Products and Biologically Derived Technology Committee of the Pharmaceutical Affairs and Food Sanitation Council
The subcommittee will deliberate whether to grant marketing approval for OBP-301 and other matters. The Company plans to begin sales of OBP-301, with esophageal cancer as the initial indication, as scheduled during the fiscal year ending December 2026.
| Item | Details |
|---|---|
| Event name | Subcommittee Meeting Concerning Marketing Approval for Oncolytic Virus OBP-301 |
| Date of occurrence | 14 May 2026 (the date the subcommittee meeting was announced; the scheduled meeting date is 21 May 2026) |
| Date recognized / date notice received | 14 May 2026 (announcement by the Ministry of Health, Labour and Welfare) |
| Subject Entity | Oncolys BioPharma Inc. |
| Target Locations / Products | Oncolytic virus OBP-301 (Suratadenoturev), with esophageal cancer as the initial indication |
| Amount of Impact on Business Performance | None (there is no impact on the Company's financial results for the fiscal year ending December 2026) |
| Accounting period in which recognized | Fiscal year ending December 2026 |
| Impact on Earnings Forecast | This matter will have no impact on the Company's financial results for the fiscal year ending December 2026. The Company plans to begin sales of OBP-301 as scheduled during the fiscal year ending December 2026. |
| Type of litigation or proceeding | Deliberation by the Pharmaceutical Affairs and Food Sanitation Council on whether to grant marketing approval and whether the product qualifies for conditional and time-limited approval |
| Court or authority | Ministry of Health, Labour and Welfare; Regenerative Medical Products and Biologically Derived Technology Committee of the Pharmaceutical Affairs and Food Sanitation Council |
| Outlook | The subcommittee will deliberate whether to grant marketing approval for OBP-301 and other matters. The Company plans to begin sales of OBP-301, with esophageal cancer as the initial indication, as scheduled during the fiscal year ending December 2026. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.